Common Cold - Pipeline Insight, 2024

Common Cold - Pipeline Insight, 2024

DelveInsight’s, ''Common Cold - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Common Cold pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Common Cold Understanding

Common colds, or simply “colds,” are usually quite harmless and go away again on their own. The symptoms of a cold such as a cough, sore throat and a runny nose can be really annoying. A severe cold can make you feel weak and ill, too. Colds usually go away on their own after about a week, but some symptoms may last longer. Although a sore throat or a stuffy nose may be gone after just a few days, it can sometimes take up to three weeks for a cough to disappear completely. Treatment with medication usually isn’t necessary. Some medications may, at best, help relieve the symptoms a bit. Because colds are typically caused by viruses, it also doesn't make sense to use antibiotics to treat an ordinary cold. Antibiotics only fight bacteria.

Colds usually take a few days to fully develop. Typical symptoms include a stuffy or runny nose, sneezing, coughing and a sore throat. Sometimes a cold is also accompanied by a mild fever, weakness, a headache and joint pain. Occasionally, colds are mistaken for the flu. But flu symptoms are usually much worse. Also, a flu doesn't develop gradually. Instead, it generally starts very suddenly with a high fever, chills, and aching muscles and joints.

""Common Cold - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Common Cold pipeline landscape is provided which includes the disease overview and Common Cold treatment guidelines. The assessment part of the report embraces, in depth Common Cold commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Common Cold collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence R&D Common Cold. The therapies under development are focused on novel approaches to treat/improve Common Cold.

Common Cold Emerging Drugs

XC-8: EURRUS Biotech

EURRUS Biotech is developing histamine glutarimide, for the treatment of asthma, common cold and other acute respiratory viral infections. The Phase II study results show XC-8 as a highly effective, oral product with no side effects. The goal of XC-8 is the long-term use with mild and moderate asthma conditions to reduce patients' corticosteroid consumption

Further product details are provided in the report……..

Common Cold: Therapeutic Assessment

This segment of the report provides insights about the Common Cold drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Common Cold

There are approx. 5+ key companies which are developing the therapies Common Cold. The companies which have their Common Cold drug candidates in the most advanced stage, i.e phase II include EURRUS Biotech

• Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Common Cold pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Common Cold: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Common Cold therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Common Cold drugs.

Common Cold Report Insights

• Common Cold Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Common Cold Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Common Cold drugs?
• How many Common Cold drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Common Cold?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Common Cold therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Common Cold and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Sanotize Research and Development
• Orbis Biosciences
• Exscientia
• EURRUS Biotech

Key Products

• Nitric oxide
• Guaifenesin extended release
• ORB 110
• IMP 1088
• XC8